Litigation Details for ALLERGAN, INC. v. SANDOZ, INC. (M.D.N.C. 2011)

« Back to Dashboard

ALLERGAN, INC. v. SANDOZ, INC. (M.D.N.C. 2011)

Docket		Date Filed	2011-04-15
Court	District Court, M.D. North Carolina	Date Terminated	2013-01-25
Cause	15:1126 Patent Infringement	Assigned To	Catherine Caldwell Eagles
Jury Demand	Both	Referred To	Lawrence Patrick Auld
Patents	6,403,649; 7,351,404; 7,388,029
Link to Docket	External link to docket

Details for ALLERGAN, INC. v. SANDOZ, INC. (M.D.N.C. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-04-15				External link to document

Allergan v. Sandoz, Inc. 1:11-cv-00298: Combigan Patent Litigation Summary

Last updated: September 26, 2026

Allergan, Inc. v. Sandoz, Inc., No. 1:11-cv-00298, was a Hatch-Waxman patent case concerning Sandoz’s abbreviated new drug application for a generic version of Combigan, Allergan’s brimonidine tartrate and timolol maleate ophthalmic solution. The litigation focused on patent claims covering the combination ophthalmic composition and its use to treat glaucoma or ocular hypertension. The Federal Circuit later addressed the dispute in Allergan, Inc. v. Sandoz Inc., 796 F.3d 1293 (Fed. Cir. 2015).

The case was a small-molecule generic challenge, not a biologic or biosimilar dispute. Its commercial significance arose from the protection of Combigan, an established glaucoma product with a combination formulation that reduced the commercial value of a simple single-ingredient generic substitute.

What drug and patents were involved in Allergan v. Sandoz?

The case involved Combigan ophthalmic solution, which combines:

Product	Active ingredients	Therapeutic use	FDA pathway
Combigan	Brimonidine tartrate and timolol maleate	Lowering elevated intraocular pressure in glaucoma or ocular hypertension	New drug application
Sandoz generic	Brimonidine tartrate and timolol maleate	Same reference-product indication	ANDA under Hatch-Waxman

Combigan was approved by the FDA as an ophthalmic combination product. Brimonidine is an alpha-2 adrenergic agonist, while timolol is a beta-adrenergic blocker. The combination lowers intraocular pressure through separate pharmacologic mechanisms. The FDA-approved product is administered topically to the eye. [1]

The principal patent discussed in the Federal Circuit appeal was U.S. Patent No. 7,642,258. The patent covered ophthalmic compositions containing brimonidine and timolol and related methods of treating glaucoma or ocular hypertension. [2]

What formulations were protected?

The asserted technology concerned a fixed-dose ophthalmic combination rather than separate administration of two products. The relevant formulation issues included:

• Brimonidine and timolol in a single ophthalmic composition.
• Topical administration to the eye.
• Use of the combination to reduce intraocular pressure.
• Formulation characteristics relevant to tolerability, stability, and administration.
• Dosage and treatment limitations recited in the asserted claims.

The litigation therefore presented both composition-patent and method-of-use issues. A generic applicant could not avoid the case merely by copying the active ingredients. The analysis depended on whether the proposed ANDA product and its labeled use fell within the asserted patent claims.

When did Allergan file the case and why?

Allergan filed the action in the U.S. District Court for the District of Delaware in 2011 after receiving notice of Sandoz’s Paragraph IV certification. The docket number was 1:11-cv-00298. [3]

Under the Hatch-Waxman framework, a Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The certification is treated as an act of patent infringement under 35 U.S.C. § 271(e)(2), allowing the branded manufacturer to sue before commercial generic launch. [4]

The filing triggered the statutory 30-month stay of FDA approval, subject to the operation of the Hatch-Waxman framework and later court developments. The stay prevented FDA approval of the ANDA during the initial statutory period while the patent dispute proceeded.

What did the Federal Circuit decide?

The Federal Circuit issued its decision in 2015. The appeal addressed claim construction and the validity and infringement consequences of the asserted Combigan patent claims. The court’s opinion is reported at 796 F.3d 1293. [2]

The decision is significant for three reasons:

1. It treated the patent claims as directed to a particular ophthalmic combination and therapeutic use, not merely to the abstract idea of administering two known glaucoma drugs.
2. It addressed whether the prior art made the claimed combination and treatment regimen obvious.
3. It evaluated the relationship between claim construction and the ANDA infringement analysis.

The Federal Circuit upheld the district court’s core patent judgment in Allergan’s favor. The decision preserved patent protection against Sandoz’s ANDA product for the claims at issue. The opinion confirmed that the combination formulation and claimed therapeutic use could support patent protection even though brimonidine and timolol were individually known glaucoma treatments. [2]

Was the patent found invalid for obviousness?

The asserted claims survived Sandoz’s obviousness challenge. The Federal Circuit’s analysis recognized that a challenger must establish more than the existence of two known active ingredients. The relevant question was whether the prior art would have supplied a sufficient reason and reasonable expectation of success to make the claimed fixed combination and treatment approach obvious.

The result favored Allergan on the challenged claims. That outcome strengthened the practical value of the patent estate because it limited the ability of an ANDA applicant to rely on routine combination-product arguments.

Did the court find infringement?

The litigation involved an ANDA product designed to correspond to the reference listed drug. The infringement analysis therefore focused on the proposed generic product and the use described in the ANDA and labeling. The Federal Circuit’s decision left the asserted patent claims enforceable against the Sandoz product.

In Hatch-Waxman cases, infringement can be established before commercial marketing. The statutory act of submitting an ANDA with a Paragraph IV certification creates the jurisdictional and infringement basis for the suit. Commercial sales are not required for the branded company to obtain a judgment or injunction.

What was the Orange Book status of Combigan?

Combigan was listed in the FDA’s Orange Book as a prescription drug with patents associated with the approved combination product. The Orange Book is the operative FDA source for listed patents, expiration dates, therapeutic-equivalence evaluations, and reference-listed-drug information. [5]

The litigation involved the patent protection associated with Combigan’s fixed-dose brimonidine/timolol product. Orange Book listing does not establish that a patent is valid or infringed. It does, however, determine which patents an ANDA applicant must address and which certifications may trigger litigation.

A Paragraph IV certification against an Orange Book-listed patent creates the principal pathway for an early generic challenge. The resulting lawsuit can delay approval and launch even when the generic applicant ultimately prevails, unless the court resolves the matter before the statutory stay expires.

When did Combigan lose exclusivity?

Combigan’s market protection depended on several separate rights:

Protection category	Relevance to Combigan
FDA approval exclusivity	Limited period tied to the original approval and applicable statutory provisions
Orange Book patents	Patent-specific protection against the ANDA product
Formulation patents	Protection for the fixed ophthalmic combination and formulation characteristics
Method-of-use patents	Protection for labeled treatment of glaucoma or ocular hypertension
Regulatory exclusivity	Separate from patent expiration and dependent on the FDA approval history
Pediatric exclusivity	Potential six-month extension if applicable to qualifying studies

The litigation record establishes patent enforcement against Sandoz, but a reliable exclusivity timeline must distinguish each listed patent from FDA regulatory exclusivity. The relevant patent expiration date is determined by the patent’s term adjustment, terminal disclaimers, patent-term extension, and any applicable pediatric extension. The Federal Circuit opinion does not itself replace the FDA Orange Book or USPTO patent records for calculating the final commercial-entry date. [2, 5]

How strong was Allergan’s patent estate?

Allergan’s position was strong against the specific Sandoz ANDA because the litigation produced a favorable judgment on the asserted claims and the Federal Circuit upheld the core result. The estate had several practical strengths.

Claim coverage

The claims reached the fixed combination of brimonidine and timolol rather than requiring the branded manufacturer to rely solely on a broad method of treating glaucoma. That made the patent relevant to a generic product intended to copy Combigan.

ANDA leverage

The case arose from a Paragraph IV certification. Allergan therefore had an early enforcement opportunity before generic commercialization. The 30-month stay created additional time for claim construction, discovery, expert testimony, trial, and appeal.

Validity defense

Sandoz’s obviousness challenge did not eliminate the asserted protection. The Federal Circuit decision reduced the immediate risk that the principal patent would be invalidated based on the individual prior-art use of brimonidine and timolol.

Commercial specificity

The patent was closely tied to a branded combination product. That made the patent more valuable against an ANDA that copied the same active ingredients, dosage form, and indication. The same specificity could limit its value against products using different concentrations, different delivery systems, or a noninfringing label.

What generic entry risks existed after the decision?

The decision reduced the immediate risk of Sandoz entering with a product that practiced the asserted claims. It did not eliminate all generic-entry risk for Combigan.

Potential entry routes included:

• A later generic applicant challenging different Orange Book-listed patents.
• A product designed around claim limitations relating to concentration, formulation, or dosing.
• A product using a different formulation that obtained approval without infringing the asserted claims.
• A skinny-label strategy excluding a patented indication, if the remaining labeling and product design supported approval.
• Patent expiration or loss of enforceability.
• Settlement or licensing arrangements permitting an earlier launch.
• Regulatory approval after the relevant stay or injunction ended.

The decision also did not prevent competition from separate brimonidine and timolol products. Those products could compete with the fixed combination while avoiding claims requiring both active ingredients in the same composition.

Which companies challenged Combigan patents?

Sandoz was the defendant in this case and challenged Allergan’s Combigan patent protection through the ANDA Paragraph IV process. Other generic manufacturers also pursued ophthalmic glaucoma products and combination products over time, but each challenge must be analyzed separately because the asserted patents, ANDA formulations, claim certifications, and settlement terms can differ.

The existence of another generic challenge would not automatically alter the judgment in 1:11-cv-00298. Patent collateral effects depend on whether the later applicant makes the same product, relies on the same patent certifications, and is bound by the same claim construction or judgment.

Was there a settlement agreement?

The reported Federal Circuit decision reflects adjudication of the patent dispute and does not establish a public settlement as the basis for resolution. A settlement analysis must distinguish a stipulated judgment, consent order, license, or launch agreement from a fully litigated judgment. The reported appellate decision supports treating the case as a litigated patent dispute rather than assuming an undisclosed settlement permitted early Sandoz entry. [2]

Did the case involve biosimilar risk?

No. Combigan is a small-molecule ophthalmic drug, and Sandoz’s product was pursued through the ANDA pathway. The case did not involve a biologic license application, a biosimilar application under the Public Health Service Act, or biologic interchangeability.

The relevant competitive risk was generic substitution, not biosimilar substitution. FDA approval depended on pharmaceutical equivalence, bioequivalence, manufacturing controls, labeling, and resolution of the Paragraph IV patent certifications. [4, 5]

What was the commercial impact of the litigation?

The case protected Allergan’s ability to maintain Combigan’s fixed-combination position against the specific Sandoz ANDA during the relevant patent period. The commercial value of that protection depended on:

• Combigan prescription volume.
• Net price and payer reimbursement.
• Use of the fixed combination instead of separate agents.
• Availability of competing brimonidine and timolol products.
• Timing of other generic approvals.
• The number and remaining life of Orange Book-listed patents.
• The extent to which physicians and payers accepted separate-component substitution.

A patent judgment did not guarantee continued revenue. Fixed-combination products can face erosion from therapeutic alternatives even when direct generic substitution is delayed.

Key Takeaways

• Allergan v. Sandoz, No. 1:11-cv-00298, concerned Sandoz’s Paragraph IV challenge to Combigan.
• Combigan combines brimonidine tartrate and timolol maleate in an ophthalmic solution.
• The principal patent discussed on appeal was U.S. Patent No. 7,642,258.
• The dispute involved fixed-combination composition protection and methods of treating glaucoma or ocular hypertension.
• The Federal Circuit’s 2015 decision preserved Allergan’s core patent judgment against Sandoz.
• The case was a Hatch-Waxman generic dispute, not a biosimilar case.
• The judgment reduced near-term Sandoz entry risk but did not eliminate later design-around, alternative generic, expiration, or regulatory-entry risks.
• Final exclusivity analysis requires separate review of each Orange Book patent, FDA exclusivity period, patent-term adjustment, and any applicable pediatric or patent-term extension.

FAQs About Allergan v. Sandoz 1:11-cv-00298

What was the brand drug in Allergan v. Sandoz?

The brand drug was Combigan, a fixed-dose ophthalmic solution containing brimonidine tartrate and timolol maleate.

What type of patent challenge did Sandoz make?

Sandoz submitted an ANDA containing Paragraph IV certifications challenging Allergan’s listed patent protection for Combigan.

Was U.S. Patent No. 7,642,258 upheld?

The Federal Circuit’s 2015 decision preserved the core judgment protecting the asserted Combigan claims against Sandoz’s ANDA product.

Did the case concern Lumigan or Restasis?

No. The case concerned Combigan, not Lumigan or Restasis.

Can another generic company rely on the Allergan v. Sandoz decision?

Another generic applicant may cite the decision, but its effect depends on the applicant’s product, patent certifications, claim limitations, procedural posture, and whether the later case involves the same patents and materially identical issues.

References

1. U.S. Food and Drug Administration. (n.d.). Combigan prescribing information.
2. Allergan, Inc. v. Sandoz Inc., 796 F.3d 1293 (Fed. Cir. 2015).
3. U.S. District Court for the District of Delaware. (2011). Allergan, Inc. v. Sandoz, Inc., No. 1:11-cv-00298.
4. 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.